{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T01:58:36Z","timestamp":1778464716553,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"General Project of Jiangsu Commission of Health","award":["M2022103"],"award-info":[{"award-number":["M2022103"]}]},{"name":"Jiangsu Province High-Level Hospital Construction Project","award":["GSPJS202504"],"award-info":[{"award-number":["GSPJS202504"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06734-6","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:53:54Z","timestamp":1770965634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Short-course high-dose cytarabine consolidation therapy before allogeneic hematopoietic stem cell transplantation improves 2-year relapse-free survival but not overall survival in patients with acute myeloid leukemia: a single-center retrospective study"],"prefix":"10.1007","volume":"105","author":[{"given":"Yu","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huifang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj Singh","family":"Dhurel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiling","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"6734_CR1","doi-asserted-by":"publisher","first-page":"e2300229","DOI":"10.1200\/GO.23.00229","volume":"9","author":"CT Jani","year":"2023","unstructured":"Jani CT, Ahmed A, Singh H, Mouchati C, Al Omari O, Bhatt PS, Sharma R, Farooq M, Liu W, Shalhoub J, Marshall D, Salciccioli JD, Warner JL, Lam P (2023) Burden of AML, 1990\u20132019: estimates from the global burden of disease study. JCO Glob Oncol 9:e2300229. https:\/\/doi.org\/10.1200\/GO.23.00229","journal-title":"JCO Glob Oncol"},{"issue":"22","key":"6734_CR2","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2009.813","volume":"301","author":"J Koreth","year":"2009","unstructured":"Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, D\u00f6hner H, Antin JH, Soiffer RJ, Cutler C (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission systematic review and Meta-analysis of prospective clinical trials. Jama-J Am Med Assoc 301(22):2349\u20132361. https:\/\/doi.org\/10.1001\/jama.2009.813","journal-title":"Jama-J Am Med Assoc"},{"issue":"4","key":"6734_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1001\/jamaoncol.2022.7605","volume":"9","author":"M Bornhauser","year":"2023","unstructured":"Bornhauser M, Schliemann C, Schetelig J, Rollig C, Kramer M, Glass B, Platzbecker U, Burchert A, Hanel M, Muller LP, Klein S, Bug G, Beelen D, Rosler W, Schafer-Eckart K, Schmid C, Jost E, Lenz G, Tischer J, Spiekermann K, Pfirrmann M, Serve H, Stolzel F, Alakel N, Middeke JM, Thiede C, Ehninger G, Berdel WE, Stelljes M (2023) Allogeneic hematopoietic cell transplantation vs standard consolidation chemotherapy in patients with Intermediate-Risk acute myeloid leukemia: A randomized clinical trial. JAMA Oncol 9(4):519\u2013526. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7605","journal-title":"JAMA Oncol"},{"issue":"1","key":"6734_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3760\/cma.j.issn.0253-2727.2017.01.010","volume":"38","author":"Y Lu","year":"2017","unstructured":"Lu Y, Wu T, Zhao YL, Cao XY, Liu DY, Zhang JP, Xiong M, Zhou JR, Sun RJ, Wei ZJ, Wang H, Liu HX, Wang T, Tong CR, Ji SQ, Lu DP (2017) [Effect of NCCN (2015) risk stratification on prognosis of patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi 38(1):44\u201349. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2017.01.010","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"6734_CR5","doi-asserted-by":"publisher","first-page":"217264","DOI":"10.1016\/j.canlet.2024.217264","volume":"605","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chang YJ, Chen J, Han M, Hu J, Hu J, Huang H, Lai Y, Liu D, Liu Q, Luo Y, Jiang EL, Jiang M, Song Y, Tang XW, Wu D, Xia LH, Xu K, Zhang X, Zhang XH, Huang X (2024) Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic Haematopoietic stem cell transplantation in china: 2024 update. Cancer Lett 605:217264. https:\/\/doi.org\/10.1016\/j.canlet.2024.217264","journal-title":"Cancer Lett"},{"key":"6734_CR6","doi-asserted-by":"publisher","first-page":"101226","DOI":"10.1016\/j.blre.2024.101226","volume":"68","author":"Q Shen","year":"2024","unstructured":"Shen Q, Gong X, Feng Y, Hu Y, Wang T, Yan W, Zhang W, Qi S, Gale RP, Chen J (2024) Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways? Blood Rev 68:101226. https:\/\/doi.org\/10.1016\/j.blre.2024.101226","journal-title":"Blood Rev"},{"issue":"12","key":"6734_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Rollig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Lowenberg B (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"issue":"12","key":"6734_CR8","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1182\/blood.2018886960","volume":"134","author":"A Venditti","year":"2019","unstructured":"Venditti A, Piciocchi A, Candoni A, Melillo L, Calafiore V, Cairoli R, de Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Luppi M, Mazza P, Martelli MP, Cuneo A, Albano F, Fabbiano F, Tafuri A, Chierichini A, Tieghi A, Fracchiolla NS, Capelli D, Foa R, Alati C, La Sala E, Fazi P, Vignetti M, Maurillo L, Buccisano F, Del Principe MI, Irno-Consalvo M, Ottone T, Lavorgna S, Voso MT, Lo-Coco F, Arcese W, Amadori S (2019) GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood 134(12):935\u2013945. https:\/\/doi.org\/10.1182\/blood.2018886960","journal-title":"Blood"},{"issue":"20","key":"6734_CR9","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1182\/blood-2012-11-468348","volume":"121","author":"HH Zhu","year":"2013","unstructured":"Zhu HH, Zhang XH, Qin YZ, Liu DH, Jiang H, Chen H, Jiang Q, Xu LP, Lu J, Han W, Bao L, Wang Y, Chen YH, Wang JZ, Wang FR, Lai YY, Chai JY, Wang LR, Liu YR, Liu KY, Jiang B, Huang XJ (2013) MRD-directed risk stratification treatment May improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood 121(20):4056\u20134062. https:\/\/doi.org\/10.1182\/blood-2012-11-468348","journal-title":"Blood"},{"issue":"15","key":"6734_CR10","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1097\/CM9.0000000000002347","volume":"136","author":"J Liu","year":"2023","unstructured":"Liu J, Wu D, Liu Q, Chang Y, Xu Y, Huang F, Huang X, Wang Y (2023) More than two courses of pre-transplant consolidation therapy benefits patients with acute myeloid leukemia in the first complete remission who underwent human leukocyte antigen-matched sibling allografts: a multicenter study. Chin Med J (Engl) 136(15):1855\u20131863. https:\/\/doi.org\/10.1097\/CM9.0000000000002347","journal-title":"Chin Med J (Engl)"},{"issue":"27","key":"6734_CR11","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","volume":"31","author":"AK Burnett","year":"2013","unstructured":"Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, Gibson BE, Wheatley K, Milligan D (2013) Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research Council AML15 trial. J Clin Oncol 31(27):3360\u20133368. https:\/\/doi.org\/10.1200\/JCO.2012.47.4874","journal-title":"J Clin Oncol"},{"issue":"1","key":"6734_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s44313-024-00041-7","volume":"59","author":"T Tan","year":"2024","unstructured":"Tan T, Bozdag SC (2024) How to improve AML outcomes? Blood Res 59(1):39. https:\/\/doi.org\/10.1007\/s44313-024-00041-7","journal-title":"Blood Res"},{"issue":"14","key":"6734_CR13","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJM199410063311402","volume":"331","author":"RJ Mayer","year":"1994","unstructured":"Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E 3rd (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and leukemia group B. N Engl J Med 331(14):896\u2013903. https:\/\/doi.org\/10.1056\/NEJM199410063311402","journal-title":"N Engl J Med"},{"issue":"11","key":"6734_CR14","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","volume":"364","author":"B van Lowenberg","year":"2011","unstructured":"Lowenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ (2011) Dutch-Belgian cooperative trial group for H-O, Swiss Group for Clinical Cancer Research Collaborative G Cytarabine dose for acute myeloid leukemia. N Engl J Med 364(11):1027\u20131036 https:\/\/doi.org\/10.1056\/NEJMoa1010222","journal-title":"N Engl J Med"},{"issue":"7","key":"6734_CR15","doi-asserted-by":"publisher","first-page":"EVIDoa2400326","DOI":"10.1056\/EVIDoa2400326","volume":"4","author":"M Hunault","year":"2025","unstructured":"Hunault M, Pautas C, Bertoli S, Dumas PY, Raffoux E, Hospital MA, Marchand T, Heiblig M, Chantepie S, Carre M, Peterlin P, Gallego-Hernanz MP, Lemasle E, Guieze R, Simand C, Turlure P, Huynh A, Leguay T, Devillier R, Quoc SN, Duployez N, Luquet I, Penther D, Celli-Lebras K, Mineur A, Raus N, Gardin C, Socie G, Cahn JY, Ifrah N, Vey N, de Latour RP, Delabesse E, Preudhomme C, Hamel JF, Pigneux A, Recher C, Dombret H (2025) Intermediate-Dose cytarabine as postinduction AML therapy. NEJM Evid 4(7):EVIDoa2400326. https:\/\/doi.org\/10.1056\/EVIDoa2400326","journal-title":"NEJM Evid"},{"issue":"24","key":"6734_CR16","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","volume":"23","author":"C Schmid","year":"2005","unstructured":"Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23(24):5675\u20135687. https:\/\/doi.org\/10.1200\/JCO.2005.07.061","journal-title":"J Clin Oncol"},{"issue":"10","key":"6734_CR17","doi-asserted-by":"publisher","first-page":"e110153","DOI":"10.1371\/journal.pone.0110153","volume":"9","author":"W Li","year":"2014","unstructured":"Li W, Gong X, Sun M, Zhao X, Gong B, Wei H, Mi Y, Wang J (2014) High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis. PLoS ONE 9(10):e110153. https:\/\/doi.org\/10.1371\/journal.pone.0110153","journal-title":"PLoS ONE"},{"issue":"1","key":"6734_CR18","doi-asserted-by":"publisher","first-page":"9509","DOI":"10.1038\/s41598-017-10368-0","volume":"7","author":"D Wu","year":"2017","unstructured":"Wu D, Duan C, Chen L, Chen S (2017) Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis. Sci Rep 7(1):9509. https:\/\/doi.org\/10.1038\/s41598-017-10368-0","journal-title":"Sci Rep"},{"issue":"6","key":"6734_CR19","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/ejh.14094","volume":"111","author":"I Sljivic","year":"2023","unstructured":"Sljivic I, Fulford A, Ho J, Lazo-Langner A, Xenocostas A, Deotare U (2023) Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis. Eur J Haematol 111(6):888\u2013894. https:\/\/doi.org\/10.1111\/ejh.14094","journal-title":"Eur J Haematol"},{"issue":"1","key":"6734_CR20","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, Yan M, Chang WC, Hsu JM, Cha JH, Hsu JL, Chou CW, Sun X, Deng Y, Chou CK, Yu D, Hung MC (2021) Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun 12(1):832. https:\/\/doi.org\/10.1038\/s41467-021-21099-2","journal-title":"Nat Commun"},{"issue":"9","key":"6734_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3760\/cma.j.issn.1009-9921.2019.09.002","volume":"28","author":"FY Shan Meng","year":"2019","unstructured":"Shan Meng FY, Fang Yanglan et al (2019) Effects of different doses of cytarabine consolidation therapy followed by haploidentical hematopoietic stem cell transplantation on low-risk and intermediate-risk acute myeloid leukemia patients. Leuk Lymphoma 28(9):516\u2013522. https:\/\/doi.org\/10.3760\/cma.j.issn.1009-9921.2019.09.002","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"6734_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2012-07-444851","volume":"121","author":"B Lowenberg","year":"2013","unstructured":"Lowenberg B (2013) Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 121(1):26\u201328. https:\/\/doi.org\/10.1182\/blood-2012-07-444851","journal-title":"Blood"},{"key":"6734_CR23","doi-asserted-by":"publisher","unstructured":"Lovewell RR, Hong J, Kundu S, Fielder CM, Hu Q, Kim KW, Ramsey HE, Gorska AE, Fuller LS, Tian L, Kothari P, Paucarmayta A, Mason EF, Meza I, Manzanarez Y, Bosiacki J, Maloveste K, Mitchell N, Barbu EA, Morawski A, Maloveste S, Cusumano Z, Patel SJ, Savona MR, Langermann S, Myint H, Flies DB, Kim TK (2023) LAIR-1 agonism as a therapy for acute myeloid leukemia. J Clin Invest 133(22). https:\/\/doi.org\/10.1172\/JCI169519","DOI":"10.1172\/JCI169519"},{"issue":"5","key":"6734_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/ncb3158","volume":"17","author":"X Kang","year":"2015","unstructured":"Kang X, Lu Z, Cui C, Deng M, Fan Y, Dong B, Han X, Xie F, Tyner JW, Coligan JE, Collins RH, Xiao X, You MJ, Zhang CC (2015) The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development. Nat Cell Biol 17(5):665\u2013677. https:\/\/doi.org\/10.1038\/ncb3158","journal-title":"Nat Cell Biol"},{"key":"6734_CR25","doi-asserted-by":"publisher","unstructured":"Horn LA, Chariou PL, Gameiro SR, Qin H, Iida M, Fousek K, Meyer TJ, Cam M, Flies D, Langermann S, Schlom J, Palena C (2022) Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-beta signaling enables PD-L1-mediated tumor eradication. J Clin Invest 132(8). https:\/\/doi.org\/10.1172\/JCI155148","DOI":"10.1172\/JCI155148"},{"key":"6734_CR26","doi-asserted-by":"publisher","first-page":"1328858","DOI":"10.3389\/fimmu.2024.1328858","volume":"15","author":"K Maurer","year":"2024","unstructured":"Maurer K, Antin JH (2024) The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy. Front Immunol 15:1328858. https:\/\/doi.org\/10.3389\/fimmu.2024.1328858","journal-title":"Front Immunol"},{"issue":"3","key":"6734_CR27","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/bjh.19628","volume":"205","author":"C Huang","year":"2024","unstructured":"Huang C, Jia Y, Yang J, Cai Y, Tong Y, Qiu H, Zhou K, Xia X, Zhang Y, Shen C, Wan L, Song X (2024) Azacitidine combined with interferon-alpha for pre-emptive treatment of AML\/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II study. Br J Haematol 205(3):1067\u20131076. https:\/\/doi.org\/10.1111\/bjh.19628","journal-title":"Br J Haematol"},{"key":"6734_CR28","doi-asserted-by":"publisher","unstructured":"Czyz A, Nagler A (2019) The role of measurable residual disease (MRD) in hematopoietic stem cell transplantation for hematological malignancies focusing on acute leukemia. Int J Mol Sci 20(21). https:\/\/doi.org\/10.3390\/ijms20215362","DOI":"10.3390\/ijms20215362"},{"issue":"5","key":"6734_CR29","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3324\/haematol.2016.159343","volume":"102","author":"SA Buckley","year":"2017","unstructured":"Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, DeFor TE, Malagola M, Anthias C, Valkova V, Kanakry CG, Gruhn B, Buccisano F, Devine B, Walter RB (2017) Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica 102(5):865\u2013873. https:\/\/doi.org\/10.3324\/haematol.2016.159343","journal-title":"Haematologica"},{"issue":"10","key":"6734_CR30","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/sj.leu.2404313","volume":"20","author":"F Buccisano","year":"2006","unstructured":"Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe MI, Cox MC, Panetta P, Consalvo MI, Mazzone C, Neri B, Ottaviani L, Fraboni D, Tamburini A, Lo-Coco F, Amadori S, Venditti A (2006) The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 20(10):1783\u20131789. https:\/\/doi.org\/10.1038\/sj.leu.2404313","journal-title":"Leukemia"},{"issue":"10","key":"6734_CR31","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jtct.2021.06.003","volume":"27","author":"E Klyuchnikov","year":"2021","unstructured":"Klyuchnikov E, Badbaran A, Massoud R, Fritsche-Friedland U, Janson D, Ayuk F, Wolschke C, Bacher U, Kroger N (2021) Enhanced immune reconstitution of gammadelta T cells after allogeneic stem cell transplantation overcomes the negative impact of pretransplantation minimal residual Disease-Positive status in patients with acute myelogenous leukemia. Transpl Cell Ther 27(10):841\u2013850. https:\/\/doi.org\/10.1016\/j.jtct.2021.06.003","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"6734_CR32","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.exphem.2004.10.008","volume":"33","author":"G Casorati","year":"2005","unstructured":"Casorati G, Locatelli F, Pagani S, Garavaglia C, Montini E, Lisini D, Turin I, Rossi F, Dellabona P, Maccario R, Montagna D (2005) Bone marrow-resident memory T cells survive pretransplant chemotherapy and contribute to early immune reconstitution of patients with acute myeloid leukemia given mafosfamide-purged autologous bone marrow transplantation. Exp Hematol 33(2):212\u2013218. https:\/\/doi.org\/10.1016\/j.exphem.2004.10.008","journal-title":"Exp Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06734-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06734-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06734-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:03:47Z","timestamp":1771949027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06734-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6734"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06734-6","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}],"article-number":"113"}}